A Preliminary Study on the Detection of Plasma Markers in Early Diagnosis for Lung Cancer
Plasma Biomarkers as a Non-invasive Approach for Early Diagnosis of Lung Cancer
Lung cancer is the most common cancer with the highest morbidity and mortality in the world. Stagement is closely related to the 5 years of survival rate of patients. The postoperative 5-year survival rate is above 90% for stage ⅠA lung cancer patients, while the 5-year survival rate of stage IV lung cancer patients is less than 5%. Therefore, early screening and diagnosis for lung cancer is a key method to reduce lung cancer mortality and prolong survival for patients.
At present, low-dose computed tomography (LDCT) is the most effective method for early detection of lung cancer. In addition to imaging examination, plasma tumor markers detection is also a common clinical detection method for tumor screening and postoperative monitoring.
Liquid biopsy is a non-invasive or minimally invasive method for testing blood or other liquid samples to analyze tumor-related markers including nucleic acids and proteins. Several studies have explored the detection of hot spot gene mutations, methylation and methylation changes of DNA, protein markers and autoantibodies in peripheral blood in lung cancer patients. Liquid biopsy has generally become the most popular field for early diagnosis of lung cancer.
Based above, it is necessary to combine multi-omics methods to improve the detection of early stage lung cancer. In our study, we intend to integrate molecular features obtained through liquid biopsy and clinical data of lung cancer patients, and develop and prospectively validate a machine-learning method which can robustly discriminate early-stage lung cancer patients from controls.
Studieoversikt
Status
Forhold
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiesteder
-
-
Beijing
-
Beijing, Beijing, Kina, 100044
- Rekruttering
- Peking University People's Hospital
-
Ta kontakt med:
- Chen Kezhong, M.D.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Enrolled patients are newly diagnosed patients
- In patients diagnosed as pulmonary nodules by imaging, benign and malignant conditions of the nodules are determined by postoperative pathology after surgical resection
- There is clear cancer stage information
- In addition to pulmonary nodules, there are no suspicious nodules of other organs
- No previous history of malignant tumor
Exclusion Criteria:
- Patients with a history of malignant tumor
- Patients with suspectednodules in other parts of the body at the time of diagnosis
- Patients who have previously received surgery, chemotherapy or radiotherapy for pulmonary lesions
- Patients with severe blood lipid in peripheral blood extracted which affects subsequent detection
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Rates of malignant and benign pulmonary nodules measured by the postoperative pathology
Tidsramme: 5 days after the surgery
|
After the sugery of each patients with pulmonary nodules, we will get the clinicopathologic characteristics of the patients.
Tumor stage and grade will be evaluated by us and rates of malignant and benign pulmonary nodules will be the primary outcome which we follow.
|
5 days after the surgery
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studieleder: Jun Wang, M.D., Peking University People's Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- PTHO1903
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Lungekreft
-
Konya City HospitalFullførtPeep By Lung Ultralyd | Peep med dynamisk etterlevelseTyrkia
-
Trakya UniversityHar ikke rekruttert ennåThoraxkirurgi | Endobronkial intubasjon | One Lung Ventillation (OLV) | Dobbel Lumen Tube Intubasjon
-
Yonsei UniversityFullført
-
Kayseri City HospitalFullførtCerebral desaturasjon | Nær infrarød spektroskopi | One Lung Ventillation (OLV) | Intraoperativ smertestillende bruk | Erector Spina Plan BlockTyrkia (Türkiye)
-
Sichuan UniversityHar ikke rekruttert ennå
-
Universitas Jenderal SoedirmanRS Prof. Dr. Margono Soekardjo PurwokertoFullførtThorax anestesi | One Lung Ventillation (OLV)Indonesia
-
The Cleveland ClinicTilbaketrukketOne Lung Ventillation (OLV) | To lungeventilasjon (TLV) | Positivt End Expiratory Pressure (PEEP) | Null sluttekspirasjonstrykk (ZEEP)
-
Novartis PharmaceuticalsFullførtNevroendokrine svulster | Avansert NET av GI Origin | Advanced NET of Lung OriginForente stater, Colombia, Italia, Taiwan, Storbritannia, Belgia, Tsjekkia, Tyskland, Japan, Saudi-Arabia, Canada, Nederland, Spania, Korea, Republikken, Libanon, Østerrike, Kina, Hellas, Sør-Afrika, Thailand, Ungarn, Tyrkia, Polen, Slov... og mer
-
Assiut UniversityHar ikke rekruttert ennåLungekreft | Lungeskade | Bleb Lung
-
RenJi HospitalRekrutteringMultiple Synchronous Lung Cancers (MSLC)Kina